Immunotherapy Trials Surge, Study Targets Cancer — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Immunotherapy trials rose from 1,257 between 2006‑2016 to 4,591 in the past decade, reflecting rapid research expansion.
- Checkpoint inhibitors reactivate immune cells to attack tumors, and dozens are approved for more than 30 cancer types.
- Herceptin binds to breast and stomach tumors, flagging them for immune destruction and blocking growth signals.
- CAR‑T therapy has produced dramatic remissions, exemplified by actor Sam Neill becoming cancer‑free after treating stage 3 blood cancer in a trial.
- Four‑year study will enroll thousands of patients with breast, bladder, kidney and skin cancers to identify factors that influence immunotherapy outcomes.
Why it matters: Patients with breast, bladder, kidney and skin cancers will gain clearer guidance on effective immunotherapies, while pharmaceutical companies will see more precise targets for drug development, accelerating approval and access.
Ask SkimNews
